Outcomes and Usability of Formoterol-Budesonide Delivered Through Synchrobreathe® in Patients With Chronic Obstructive Pulmonary Disease: The EMERGE StudyDRUGS-REAL WORLD OUTCOMESIF1.92025-10-010PRE
Efficacy of Budesonide/Glycopyrronium/Formoterol FDC across blood eosinophil ranges in Indian COPD patients: post-hoc analysis of a phase-IV clinical-trialEUROPEAN RESPIRATORY JOURNALIF212024-10-300PRE
Real-world study of formoterol/budesonide delivered through BAI in COPD patientsEUROPEAN RESPIRATORY JOURNALIF212023-10-270PRE
Effectiveness and safety of salmeterol/fluticasone fixed-dose combination delivered through Synchrobreathe(R) in patients with asthma: the real-world EVOLVE studytherapeutic advances in musculoskeletal diseaseIF32022-12-151OAAI
Fixed-dose combination of three drugs, i.e. LABA/LAMA/ICS for COPD: Results of a real-world study from IndiaPULMONARY PHARMACOLOGY & THERAPEUTICSIF2.82020-08-010PREAI
Real-world evaluation of the clinical safety and efficacy of fluticasone/formoterol FDC via the Revolizer® in patients with persistent asthma in IndiaPULMONARY PHARMACOLOGY & THERAPEUTICSIF2.82020-02-016PREAI
Device-handling study of a novel breath-actuated inhaler, Synchrobreathe®, versus a pMDIRESPIRATORY MEDICINEIF3.12020-01-0111PREAI
Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPDEUROPEAN RESPIRATORY JOURNALIF212019-11-211PRE
Device handling study of a novel breath actuated inhaler Synchrobreathe vs pMDIEUROPEAN RESPIRATORY JOURNALIF212019-11-210PRE
Comparison of fluticasone/formoterol with budesonide/formoterol pMDI in adults with moderate to severe persistent asthma: Results from a 12-week randomized controlled trialPULMONARY PHARMACOLOGY & THERAPEUTICSIF2.82018-02-0110PREAI
Clinical evaluation of fluticasone/formoterol twice daily delivered via a single dose dry powder inhaler in patients with persistent asthmaEUROPEAN RESPIRATORY JOURNALIF212016-11-080PRE
LATE-BREAKING ABSTRACT: Effects of a fixed dose once-daily triple drug combination in smokers and non-smokers with COPDEUROPEAN RESPIRATORY JOURNALIF212016-11-080PRE
Regulatory Considerations for Approval of Generic Inhalation Drug Products in the US, EU, Brazil, China, and IndiaAAPS JOURNALIF3.72015-05-2354OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向